Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 702-711

  Sui, Ziye ^a   Fan, Shongshan ^a   Sniderhan, Lynn ^a   Reisinger, Elizabeth ^a   Litzburg, Angela ^a   Schifitto, Giovanni ^a   Gelbard, Harris A ^a   Dewhurst, Stephen ^a,b   Maggirwar, Sanjay B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 1347; GENE PRODUCT; GLYCOPROTEIN GP 120; MITOGEN ACTIVATED PROTEIN KINASE P38; MIXED LINEAGE KINASE 3; NEUROTOXIN; STRESS ACTIVATED PROTEIN KINASE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DEMENTIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 ASSOCIATED DEMENTIA; MONOCYTE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

EID: 33745317973     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.702     Document Type: Article

References (83)

1. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81: 807-869.
2. Gallo, K. A., and G. L. Johnson. 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell. Biol. 3: 663-672.
3. Silva, R. M., C. Y. Kuan, P. Rakic, and R. E. Burke. 2005. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. 20: 653-664.
4. Wang, L. H., C. G. Besirli, and E. M. Johnson, Jr. 2004. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44: 451-474.
5. Barber, S, A., J. L. Uhrlaub, J. B. DeWitt, P. M. Tarwater, and M. C. Zink. 2004. Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am. J. Pathol 164: 355-362.
6. Johnson, G. V., and C. D. Bailey. 2003. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp. Neurol. 183: 263-268.
7. Harper, S. J., and N. Wilkie. 2003. MAPKs: new targets for neurodegeneration. Expert Opin. Ther. Targets 7: 187-200.
8. Barone, F. C., and A. A. Parsons. 2000. Therapeutic potential of antiinflammatory drugs in focal stroke. Expert Opin. Invest. Drugs 9: 2281-2306.
9. Kuan, C. Y., and R. E. Burke. 2005. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr. Drug Targets CNS Neurol. Disord. 4: 63-67.
10. IIIB-induced neurotoxicity. J. Neurochem. 82: 1424-1434.
11. Mota, M., M. Reeder, J. Chernoff, and C. E. Bazenet. 2001. Evidence for a role of mixed lineage kinases in neuronal apoptosis. J. Neurosci. 21: 4949-4957.
12. Barthwal, M. K., P. Sathyanarayana, C. N. Kundu, B. Rana, A. Pradeep, C. Sharma, J. R. Woodgett, and A. Rana. 2003. Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J. Biol. Chem. 278: 3897-3902.
13. Yin, X. H., Q. G. Zhang, B. Miao, and G. Y. Zhang. 2005. Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. J. Neurochem. 93: 1021-1029.
14. Maroney, A. C., J. P. Finn, T. J. Connors, J. T. Durkin, T. Angeles, G. Gessner, Z. Xu, S. L. Meyer, M. J. Savage, L. A. Greene, et al. 2001. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276: 25302-25308.
15. Roux, P. P., G. Dorval, M. Boudreau, A. Angers-Loustau, S. J. Morris, J. Makkerh, and P. A. Barker. 2002. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J. Biol. Chem. 277: 49473-49480.
16. Lotharius, J., J. Falsig, J. van Beek, S. Payne, R. Dringen, P. Brundin, and M. Leist. 2005. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25: 6329-6342.
17. +-induced neurotoxicity in SH-SY5Y cells. Brain Res. 1003: 86-97.
18. Saporito, M. S., E. M. Brown, M. S. Miller, and S. Carswell. 1999. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J. Pharmacol. Exp. Ther. 288: 421-427.
19. Saporito, M. S., R. L. Hudkins, and A. C. Maroney. 2002. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. 40: 23-62.
20. Group, P. S. 2004. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 62: 330-332.
21. Wu, S. S., and S. J. Frucht. 2005. Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 19: 723-743.
22. Bozyczko-Coyne, D., T. M. O'Kane, Z. L. Wu, P. Dobrzanski, S. Murthy, J. L. Vaught, and R. W. Scott. 2001. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with αβ-induced cortical neuron apoptosis. J. Neurochem. 77: 849-863.
23. Glass, J. D., H. Fedor, S. L. Wesselingh, and J. C. McArthur. 1995. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neural 38: 755-762.
24. Dou, H., J. D. Kingsley, R. L. Mosley, H. A. Gelbard, and H. E. Gendelman. 2004. Neuroprotective strategies for HIV-1 associated dementia. Neurotox. Res. 6: 503-521.
25. Persidsky, Y., and H. E. Gendelman. 2003. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J. Leukocyte Biol. 74: 691-701.
26. New, D. R., S. B. Maggirwar, L. G. Epstein, S. Dewhurst, and H. A. Gelbard. 1998. HIV-1 Tat induces neuronal death via tumor necrosis factor-α and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism. J. Biol. Chem. 273: 17852-17858.
27. Perry, S. W., J. P. Norman, A. Litzburg, and H. A. Gelbard. 2004. Antioxidants are required during the early critical period, but not later, for neuronal survival. J. Neurosci. Res. 78: 485-492.
28. Brewer, G. J., J. R. Torricelli, E. K. Evege, and P. J. Price. 1993. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35: 567-576.
29. Fan, S., C. A. Maguire, S. H. Ramirez, B. Bradel-Tretheway, R. Sapinoro, Z. Sui, S. Chakraborty-Sett, and S. Dewhurst. 2005. Valproic acid enhances gene expression from viral gene transfer vectors. J. Virol. Methods 125: 23-33.
30. Ramirez, S. H., J. F. Sanchez, C. A. Dimitri, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar. 2001. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-κB (NF-κB)-dependent mechanism. J. Neurochem. 78: 874-889.
31. Leung, I. W., and N. Lassam. 2001. The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J. Biol. Chem. 276: 1961-1967.
32. Du, Y., B. C. Bock, K. A. Schachter, M. Chao, and K. A. Gallo. 2005. Cdc42 induces activation loop phosphorylation and membrane targeting of MLK3. J. Biol. Chem. 280: 42984-42993.
33. Yabe, T., J. T. Herbert, A. Takanohashi, and J. P. Schwartz. 2004. Treatment of cerebellar granule cell neurons with the neurotrophic factor pigment epithelium-derived factor in vitro enhances expression of other neurotrophic factors as well as cytokines and chemokines. J. Neurosci. Res. 77: 642-652.
34. Xu, Z., A. C. Maroney, P. Dobrzanski, N. V. Kukekov, and L. A. Greene. 2001. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol. Cell. Biol. 21: 4713-4724.
35. + peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J. Neurovirol. 7: 528-541.
36. Pu, H., J. Tian, G. Flora, Y. W. Lee, A. Nath, B. Hennig, and M. Toborek. 2003. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol. Cell. Neurosci. 24: 224-237.
37. Edelstein, H., and R. T. Knight. 1987. Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet 2: 341-342.
38. Berger, J. R., and G. Arendt. 2000. HIV dementia: the role of the basal ganglia and dopaminergic systems. J. Psychopharmacol. 14: 214-221.
39. Koutsilieri, E., S. Sopper, C. Scheller, V. ter Meulen, and P. Riederer. 2002. Parkinsonism in HIV dementia. J. Neurol Transm. 109: 767-775.
40. Tse, W., M. G. Cersosimo, J. M. Gracies, S. Morgello, C. W. Olanow, and W. Koller. 2004. Movement disorders and AIDS: a review. Parkinsonism Relat. Disord. 10: 323-334.
41. Hersh, B. P., P. R. Rajendran, and D. Battinelli. 2001. Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART. Neurology 56: 278-279.
42. Mattos, J. P., A. L. Rosso, R. B. Correa, and S. A. Novis. 2002. Movement disorders in 28 HIV-infected patients. Ar. Qneuropsiquiatr. 60: 525-530.
43. Sardar, A. M., C. Czudek, and G. P. Reynolds. 1996. Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7: 910-912.
44. IIIB- and nucleoside analogue-induced sensory neuron toxicity. Exp. Neurol. 188: 246-253.
45. Song, L., A. Nath, J. D. Geiger, A. Moore, and S. Hochman. 2003. Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site. J. Neurovirol. 9: 399-403.
46. Eugenin, E. A., T. G. D'Aversa, L. Lopez, T. M. Calderon, and J. W. Berman. 2003. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85: 1299-1311.
47. IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells. Neurosci. Lett.
48. Savio, T., and G. Levi. 1993. Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J. Neurosci. Res. 34: 265-272.
49. Haughey, N. J., and M. P. Mattson. 2002. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J. Acquir. Immune Defic. Syndr. 31(Suppl. 2):S55-S61.
50. Harris-White, M. E., and S. A. Frautschy. 2005. Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr. Drug Targets CNS Neurol. Dlsord. 4: 469-480.
51. Liu, Y., M. Jones, C. M. Hingtgen, G. Bu, N. Laribee, R. E. Tanzi, R. D. Moir, A. Nath, and J. J. He. 2000. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6: 1380-1387.
52. Pocernich, C. B., R. Sultana, E. Hone, J. Turchan, R. N. Martins, V. Calabrese, A. Nath, and D. A. Butterfield. 2004. Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes. J. Neurosci. Res. 77: 532-539.
53. Borsello, T., K. Croquelois, J. P. Hornung, and P. G. Clarke. 2003. N-Methyl-D-aspartate-triggered neuronal death in organotypic hippocampal cultures is endocytic, autophagic and mediated by the c-Jun N-terminal kinase pathway. Eur J. Neurosci. 18: 473-485.
54. +-mediated activation of c-Jun N-terminal kinase and nuclear factor κB by NMDA in cortical cell cultures. J. Neurochem. 71: 1390-1395.
55. Kawasaki, H., T. Morooka, S. Shimohama, J. Kimura, T. Hirano, Y. Gotoh, and E. Nishida. 1997. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 272: 18518-18521.
56. Everall, I. P., L. A. Hansen, and E. Masliah. 2005. The shifting patterns of HIV encephalitis neuropathology. Neurotox. Res. 8: 51-62.
57. Everall, I. P. 2000. Neuronal damage: recent issues and implications for therapy. J. Neurovirol. 6(Suppl. 1): S103-S105.
58. Ketzler, S., S. Weis, H. Haug, and H. Budka. 1990. Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol. 80: 92-94.
59. Gray, F., H. Adle-Biassette, F. Brion, T. Ereau, I. le Maner, V. Levy, and G. Corcket. 2000. Neuronal apoptosis in human immunodeficiency virus infection. J. Neurovirol. 6(Suppl. 1): S38-S43.
60. Gelbard, H. A., H. J. James, L. R. Sharer, S. W. Perry, Y. Saito, A. M. Kazee, B. M. Blumberg, and L. G. Epstein. 1995. Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neuropathol. Appl. Neurobiot. 21: 208-217.
61. Gonzalez-Scarano, F., and J. Martin-Garcia. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol 5: 69-81.
62. Singh, I. N., N. El-Hage, M. E. Campbell, S. E. Lutz, P. E. Knapp, A. Nath, and K. F. Hauser. 2005. Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neunte degeneration in striatal neurons. Neuroscience 135: 781-790.
63. Sheng, W. S., S. Hu, C. C. Hegg, S. A. Thayer, and P. K. Peterson. 2000. Activation of human microglial cells by HIV-1 gp41 and Tat proteins. Clin. Immunol. 96: 243-251.
64. D'Aversa, T. G., E. A. Eugenin, and J. W. Berman. 2005. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J. Neurosci. Res. 81: 436-446.
65. Lund, S., P. Porzgen, A. L. Mortensen, H. Hasseldam, D. Bozyczko-Coyne, S. Morath, T. Hartung, M. Bianchi, P. Ghezzi, M. Bsibsi, et al. 2005. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J. Neurochem. 92: 1439-1451.
66. Ciallella, J. R., M. Saporito, S. Lund, M. Leist, H. Hasseldam, N. McGann, C. S. Smith, D. Bozyczko-Coyne, and D. G. Flood. 2005. CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-α release from lipopolysaccharide-treated cells and mice. Eur. J. Pharmacol. 515: 179-187.
67. Zink, M. C., G. D. Coleman, J. L. Mankowski, R. J. Adams, P. M. Tarwater, K. Fox, and J. E. Clements. 2001. Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J. Infect. Dis. 184: 1015-1021.
68. Sevigny, J. J., S. M. Albert, M. P. McDermott, J. C. McArthur, N. Sacktor, K. Conant, G. Schifitto, O. A. Seines, Y. Stern, D. R. McClernon, et al. 2004. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63: 2084-2090.
69. Mankowski, J. L., S. E. Queen, J. E. Clements, and M. C. Zink. 2004. Cerebrospinal fluid markers that predict SIV CNS disease. J. Neuroimmunol. 157: 66-70.
70. Kelder, W., J. C. McArthur, T. Nance-Sproson, D. McClernon, and D. E. Griffin. 1998. β-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 44: 831-835.
71. Gonzalez, E., B. H. Rovin, L. Sen, G. Cooke, R. Dhanda, S. Mummidi, H. Kulkarni, M. J. Bamshad, V. Telles, S. A. Anderson, et al. 2002. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl. Acad. Sci. USA 99: 13795-13800.
72. Glass, J. D., S. L. Wesselingh, O. A. Seines, and J. C. McArthur. 1993. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 43: 2230-2237.
73. Conant, K., A. Garzino-Demo, A. Nath, J. C. McArthur, W. Halliday, C. Power, R. C. Gallo, and E. O. Major. 1998. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc. Natl. Acad. Sci. USA 95: 3117-3121.
74. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, K. M. Yamada, and S. Dhawan. 1997. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J. Immunol. 159: 4077-4083.
75. Nath, A., K. Conant, P. Chen, C. Scott, and E. O. Major. 1999. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes: a hit and run phenomenon. J. Biol. Chem. 274: 17098-17102.
76. Fotheringham, J., M. Mayne, C. Holden, A. Nath, and J. D. Geiger. 2004. Adenosine receptors control HIV-1 Tat-induced inflammatory responses through protein phosphatase. Virology 327: 186-195.
77. Mayne, M., C. P. Holden, A. Nath, and J. D. Geiger. 2000. Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-α production in human macrophages. J. Immunol. 164: 6538-6542.
78. Albini, A., S. Ferrini, R. Benelli, S. Sforzini, D. Giunciuglio, M. G. Aluigi, A. E. Proudfoot, S. Alouani, T. N. Wells, G. Mariani, et al. 1998. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. USA 95: 13153-13158.
79. Contreras, X., Y. Bennasser, N. Chazal, M. Moreau, C. Leclerc, J. Tkaczuk, and E. Bahraoui. 2005. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-α production. Virology 332: 316-328.
80. Yi, Y., C. Lee, Q. H. Liu, B. D. Freedman, and R. G. Collman. 2004. Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: implications for neuropathogenesis. J. Neurovirol. 10(Suppl. 1): 91-96.
81. Del Corno, M., Q. H. Liu, D. Schols, E. de Clercq, S. Gessani, B. D. Freedman, and R. G. Collman. 2001. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98: 2909-2916.
82. D'Aversa, T. G., K. O. Yu, and J. W. Berman. 2004. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J. Neurovirol. 10: 86-97.
83. Brancho, D., J. J. Ventura, A. Jaeschke, B. Doran, R. A. Flavell, and R. J. Davis. 2005. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol. 25: 3670-3681.